Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 1,706Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 17Xarelto

02 2Xarelto

03 1XareltoTM

PharmaCompass

01

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 5,461

2019 Revenue in Millions : 4,991

Growth (%) : 9

blank

02

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 2,345

2019 Revenue in Millions : 2,313

Growth (%) : 1

blank

03

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 5,213

2020 Revenue in Millions : 5,461

Growth (%) : 5

blank

04

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 2,438

2020 Revenue in Millions : 2,345

Growth (%) : 4

blank

05

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 4,742

2021 Revenue in Millions : 5,213

Growth (%) : -9

blank

06

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 2,473

2021 Revenue in Millions : 2,438

Growth (%) : 1

blank

07

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 2,365

2022 Revenue in Millions : 2,473

Growth (%) : -4

blank

08

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 4,428

2022 Revenue in Millions : 4,742

Growth (%) : -10

blank

09

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Anticoagulants

Currency : USD

2014 Revenue in Millions : 76.20%

2013 Revenue in Millions :

Growth (%) :

blank

10

Brand Name : Xarelto

Rivaroxaban

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xarelto

arrow
2024 ACI Convention
Not Confirmed

Rivaroxaban

Main Therapeutic Indication : Anticoagulants

Currency : USD

2015 Revenue in Millions : 1,847

2014 Revenue in Millions : 2,477

Growth (%) : 34%

blank